Platinum doublet vs non‐platinum therapy
12‐month survival rates · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower 12‐month survival rates compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable… 2023 · Cochrane Headline outcomes onlyRR 0.92 [0.87, 0.97]11 studies · 1567 participantsModerate